{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:50:51Z","timestamp":1760237451799,"version":"build-2065373602"},"reference-count":26,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Background: We aimed to compare the clinical outcomes between intraperitoneal chemotherapy and dose-dense chemotherapy for the frontline treatment of advanced ovarian, fallopian tube and primary peritoneal cancer in women not receiving bevacizumab. Methods: All consecutive women with stage II~IV cancer treated with either frontline intraperitoneal or dose-dense platinum\/paclitaxel chemotherapy and not receiving bevacizumab between March 2006 and June 2019 were reviewed. Results: A total of 50 women (intraperitoneal group, n = 22; dose-dense group, n = 28) were reviewed. Median progression-free survival (32.6 months versus 14.2 months; adjusted hazard ratio = 0.38; 95% CI = 0.16 to 0.90, p = 0.03) and overall survival (not reached versus 30.7 months; adjusted hazard ratio = 0.23, 95% CI = 0.07 to 0.79, p = 0.02) were significantly higher in the intraperitoneal group than in the dose-dense group. A multivariable Cox proportional-hazards model also indicated that the number of frontline chemotherapy cycles (adjusted hazard ratio = 0.66, 95% CI 0.47 to 0.94, p = 0.02) was a predictor of better overall survival. Nausea\/vomiting and nephrotoxicity occurred more frequently in the intraperitoneal group (p = 0.02 and &lt;0.0001, respectively). Conclusions: Intraperitoneal chemotherapy seems to be superior in progression free survival and overall survival to dose-dense chemotherapy in the frontline treatment of women with optimally resected advanced ovarian, fallopian tube or primary peritoneal cancer and not receiving bevacizumab.<\/jats:p>","DOI":"10.3390\/ijerph17103603","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T11:31:18Z","timestamp":1590060678000},"page":"3603","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparisons of Clinical Outcomes in Women with Advanced Ovarian Cancer Treated with Frontline Intraperitoneal versus Dose-Dense Platinum\/Paclitaxel Chemotherapy without Bevacizumab"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9450-2834","authenticated-orcid":false,"given":"Wan-Hua","family":"Ting","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Huang","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology and Hematology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6299-1888","authenticated-orcid":false,"given":"Hui-Hua","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chow","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Hsiung","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan"},{"name":"Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei 100225, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4381-9564","authenticated-orcid":false,"given":"Sheng-Mou","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan"},{"name":"Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei 100225, Taiwan"},{"name":"Graduate School of Biotechnology and Bioengineering, Yuan Ze University, Taoyuan 320315, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","article-title":"Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2013.04.001","article-title":"Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study","volume":"130","author":"Landrum","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG Oncology\/Gynecologic Oncology Group study","volume":"37","author":"Walker","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejogrb.2019.10.047","article-title":"A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma","volume":"244","author":"Rettenmaier","year":"2020","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Bio."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: Prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","article-title":"Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125","volume":"14","author":"Rustin","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/jnci\/92.18.1534","article-title":"Re: New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup","volume":"92","author":"Vergote","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ygyno.2008.09.033","article-title":"Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum","volume":"112","author":"Hsiao","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejogrb.2020.02.038","article-title":"Letter to the Editor on \u201cA retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy\u201d","volume":"247","author":"Hsiao","year":"2020","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ygyno.2019.12.016","article-title":"Intraperioneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer","volume":"156","author":"Bixel","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1040-8428(02)00109-9","article-title":"Weekly administration of paclitaxel: Theoretical and clinical basis","volume":"44","author":"Marchetti","year":"2002","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ctrv.2012.04.004","article-title":"Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance","volume":"39","author":"Pinato","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/jnci\/89.7.480","article-title":"Pharmacokinetic Problems in Peritoneal Drug Administration: Tissue Penetration and Surface Exposure","volume":"89","author":"Dedrick","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/jjco\/hyq182","article-title":"A randomized Phase II\/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer","volume":"41","author":"Fujiwara","year":"2011","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/0008-5472.CAN-12-2225","article-title":"Dose-dense chemotherapy improves mechanisms of antitumor immune response","volume":"73","author":"Chang","year":"2013","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/onc.2015.82","article-title":"Hyperthermic intraperitoneal chemotherapy leads to an anticancer immune response via exposure of cell surface heat shock protein 90","volume":"35","author":"Zunino","year":"2016","journal-title":"Oncogene"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ygyno.2009.05.034","article-title":"Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer","volume":"114","author":"Yen","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0020-7292(00)00340-4","article-title":"Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer","volume":"72","author":"Yen","year":"2001","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1525-1438.2008.01192.x","article-title":"Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer","volume":"18","author":"Nagao","year":"2008","journal-title":"Int. J. Gynecol. Cancer"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/17\/10\/3603\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:30:56Z","timestamp":1760175056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/17\/10\/3603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["ijerph17103603"],"URL":"https:\/\/doi.org\/10.3390\/ijerph17103603","relation":{},"ISSN":["1660-4601"],"issn-type":[{"type":"electronic","value":"1660-4601"}],"subject":[],"published":{"date-parts":[[2020,5,20]]}}}